Get started
Author

Pia Baumann

Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
2009 · Pia Baumann, Jan Nyman, et al. · Journal of Clinical Oncology · 841
PDF
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 · G. D'Addario, M. Früh, et al. · Annals of Oncology · 328
PDF
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries
2006 · Pia Baumann, Jan Nyman, et al. · Acta Oncologica · 224
PDF
Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study
2008 · Pia Baumann, Jan Nyman, et al. · Radiotherapy and Oncology · 143
Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy
2011 · Heike Peulen, Kristin Karlsson, et al. · Radiotherapy and Oncology · 121
Dose distributions in SBRT of lung tumors: Comparison between two different treatment planning algorithms and Monte-Carlo simulation including breathing motions
2006 · Ingmar Lax, Vanessa Panettieri, et al. · Acta Oncologica · 70
PDF
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer
2020 · Mohammad Jahanzeb, Huamao M. Lin, et al. · Clinical Lung Cancer · 65
Retrospective Cohort Study of Bronchial Doses and Radiation-Induced Atelectasis After Stereotactic Body Radiation Therapy of Lung Tumors Located Close to the Bronchial Tree
2013 · Kristin Karlsson, Jan Nyman, et al. · International Journal of Radiation Oncology*Biology*Physics · 39
NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction
2011 · Berit M. Wennberg, Pia Baumann, et al. · Acta Oncologica · 35
PDF
Real-World Treatment Duration in ALK-Positive Non-Small-Cell Lung Cancer Patients Receiving Brigatinib Through the Early Access Program
2020 · Huamao M Lin, Xiaoyun Pan, et al. · Future Oncology · 12
PDF
Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer
2006 · Emma Djärv, Jan Nyman, et al. · Acta Oncologica · 9
PDF
Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)
2019 · M.M. Lin, X. Pan, et al. · Annals of Oncology · 7
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
2024 · Ruth Plummer, Alastair Greystoke, et al. · Journal of Hepatocellular Carcinoma · 4
PDF
Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States
2019 · X. Pan, M.M. Lin, et al. · Annals of Oncology · 3
986P Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study
2024 · H. Chon, J. Heo, et al. · Annals of Oncology · 1
PDF
First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC).
2024 · Maria Reig, T.R. Jeffry Evans, et al. · Journal of Clinical Oncology · 1
PDF
Pcn308 Real-world Utilization of Brigatinib in Patients With Non–small Cell Lung Cancer (nsclc)
2019 · H.M. Lin, X. Pan, et al. · Value in Health · 1
Stereotactic Body Radiotherapy in Non-Small Cell Lung Cancer
2009 · Pia Baumann · Figshare · 1
Supplementary Data1 from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
2026 · Hong Jae Chon, Jeong Heo, et al.
Data from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
2026 · Hong Jae Chon, Jeong Heo, et al.
A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
2026 · Hong Jae Chon, Jeong Heo, et al. · Clinical Cancer Research
176P Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma
2024 · H.J. Chon, J. Heo, et al. · Annals of Oncology
PDF
P2.16-44 Real-World Treatment Patterns and Outcomes in ALK+ NSCLC Patients Receiving Immuno-Oncology Therapy in the United States
2019 · X. Pan, H. Lin, et al. · Journal of Thoracic Oncology
A Retrospective Study of Bronchial Doses and Radiation-induced Atelectasis After SBRT of Lung Tumors Located Close to the Bronchial Tree
2012 · K. Karlsson, J. Nyman, et al. · International Journal of Radiation Oncology*Biology*Physics
Erratum
2010 · Christian Plank, Kai-Dietrich Nüsken, et al. · American Journal of Nephrology
PDF
Works count: 26
Citation count: 1,905
H-index: 10
I10-index: 10
Year
Topic
Type